Evotec secures $2.9 million grant to advance early drug safety testing

On November 16, 2026 Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) reported that it has been awarded a new $2.9 million grant by the Gates Foundation to support continued use of its human stem cell-based New Approach Methodologies (NAMs) for identifying potential safety risks to fetal development in novel drug candidates. The funding extends a project initiated in 2023 for a further three years, providing researchers working on global health programs with continued access to technology that can help assess potential risks earlier in drug discovery.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Joanna Holbrook, Chief Scientific Officer of Evotec, said:

"Identifying potential safety risks early in the drug development process is essential to the efficient advancement of better medicines for global health priorities. Our platform allows researchers to investigate potential effects on prenatal development based on the behavior of human cells, helping them make better-informed decisions about which drug candidates to pursue and minimizing the risk of costly and time-consuming changes in course later in the process. The continued funding support of the Gates Foundation is an important recognition of the potential value of this approach, and we are pleased to extend access to this technology for global health research."

Evotec’s platform combines human induced pluripotent stem cell (hiPSC) models with industrial-scale screening capabilities to model aspects of human development and to identify compounds that may pose developmental risks.

Over the course of the initial three-year collaboration, more than 5,000 compounds were screened across nine grantee programs, highlighting the platform’s ability to generate human-relevant safety data at scale. The development and validation of the platform are described in a recent bioRxiv preprint.

Evotec’s human stem cell-based platform forms part of its broader capabilities in New Approach Methodologies, which can potentially reduce reliance on animal testing and help improve research efficiency.

(Press release, Evotec, NOV 16, 2026, View Source [SID1234674807])